Case reports 1 and the high tumor mutational burden 2 of basal cell carcinomas (BCCs) compared with other tumor types suggest that programmed death-ligand 1 (PD-L1) inhibitors may be active against advanced BCCs. Many advanced BCCs are refractory to 3 or are recurrent 4 after hedgehog pathway inhibitors, and therefore PD-L1 inhibitors could be a useful therapeutic option. We present a proof-of-principle, nonrandomized, open-label study of pembrolizumab (200 mg intravenously every 3 weeks), with or without vismodegib (150 mg orally daily), for eligible subjects with advanced BCCs. The primary outcome was the overall response rate (ORR) for all evaluable subjects at 18 weeks.
The median time to response for all responders (n = 6) was 10.4 weeks (range 8.4-17.4 weeks) . The median duration of response for all responders (n = 6) was 67.3 weeks (range 28.0-82.0 weeks; Table I ).
One-year progression-free survival probability was 70%, and the 1-year overall survival probability was 94% for all evaluable subjects (n = 16; Table I ).
Before pembrolizumab, 29% (2/7 patients) expressed PD-L1 at ≥1% of tumor cells. There was no significant correlation between prepembrolizumab PD-L1 expression and best percentage change in BCC diameter.
There were no life-threatening adverse events (AEs) or deaths during the study. Three severe (grade 3) AEs occurred out of 98 AEs from 16 participants. Only 1 of the severe AEs, hyponatremia, was attributed to pembrolizumab. There were 23 immune-related AEs, with dermatitis and fatigue as the most common (all grade 1 or 2), and only 1 severe immunerelated AE (the aforementioned hyponatremia).
As a proof-of-principle study, we conclude that pembrolizumab is active against BCCs. Although the 2 groups were not directly compared, the response rate of the pembrolizumab plus vismodegib group was not superior to the monotherapy group. The lack of lifethreatening AEs or death suggests that pembrolizumab has a reasonable safety profile in patients with BCC.
This study is limited by its sample size, because advanced BCCs are an uncommon disease. Nevertheless, the efficacy and safety data presented here could be used in future metaanalyses and compared with forthcoming multi-institutional studies on PD-L1 inhibitors against advanced BCCs. 
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